Healthcare
Traws Pharma, Inc.(TRAW)
Live Price
Offline$0.85
+6.25% today
1Y Change
-25.15%
Window
Jun 20, 2025 โ Jun 10, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +1134.5%
- EPS Growth
- +102.4%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 20, 2025 โ Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Traws Pharma, Inc. (TRAW) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.85 and down 25.1% across the available one-year price window (Jun 20, 2025 โ Jun 10, 2026). Baseline metrics include revenue growth of +1134.5%, EPS growth of +102.4%, a dividend yield of 0.0%. What stands out right now is revenue +1134.5%, EPS +102.4%, free cash flow +30.3% with operating margin -190.1% and ROIC 1002.6%. Valuation sits in the middle of the pack at price/sales 4.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TRAW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+1134.5% vs +7.6% peer median
Operating Margin
Below sector median
-190.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1134.5% and EPS at +102.4%, with operating margin around -190.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +0.0% | -2.0% | โ |
2026 May 14, 2026 | โ | +15.3% | -8.6% | โ |
2025 Nov 13, 2025 | +96.3% | +22.6% | +20.9% | +31.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRAW
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TRAW Max Drawdown
-65.18%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TRAW and SPY.
Company Overview
Traws Pharma, Inc.
NASDAQ Global Market
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
- Leadership
- Iain D. Dukes
- IPO Date
- Jul 25, 2013
- Employees
- 6
- Street Address
- 12 Penns Trail
- Mailing
- Newtown, PA, 18940
- Region
- Newtown, PA, US
- Reporting Currency
- USD
- Investor Line
- 267 759 3680
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.4
- Price/Book
- โ
Growth
- Revenue
- +1134.5%
- EPS
- +102.4%
- Free Cash Flow
- +30.3%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -190.1%
- Net Margin
- -141.6%
- ROE
- -103.5%
- ROIC
- 1002.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.